Literature DB >> 10066828

Role of interleukin (IL)-2 receptor beta-chain subdomains and Shc in p38 mitogen-activated protein (MAP) kinase and p54 MAP kinase (stress-activated protein Kinase/c-Jun N-terminal kinase) activation. IL-2-driven proliferation is independent of p38 and p54 MAP kinase activation.

A E Hunt1, F V Lali, J D Lord, B H Nelson, T Miyazaki, K J Tracey, B M Foxwell.   

Abstract

We have shown recently that interleukin (IL)-2 activates the mitogen-activated protein (MAP) kinase family members p38 (HOG1/stress-activated protein kinase II) and p54 (c-Jun N-terminal kinase/stress-activated protein kinase I). Furthermore, the p38 MAP kinase inhibitor SB203580 inhibited IL-2-driven T cell proliferation, suggesting that p38 MAP kinase might be involved in mediating proliferative signals. In this study, using transfected BA/F3 cell lines, it is shown that both the acidic domain and the membrane-proximal serine-rich region of the IL-2Rbeta chain are required for p38 and p54 MAP kinase activation and that, as for p42/44 MAP kinase, this activation requires the Tyr338 residue of the acidic domain, the binding site for Shc. It is well established that the acidic domain of the IL-2Rbeta chain is dispensable for IL-2-driven proliferation, and thus our observations suggest that neither p38 nor p54 MAP kinase activation is required for IL-2-driven proliferation of BA/F3 cells. In addition, the tetravalent guanylhydrazone inhibitor of proinflammatory cytokine production, CNI-1493, can block the activation of p54 and p38 MAP kinases by IL-2 but has no effect on IL-2-driven proliferation of BA/F3 cells, activated primary T cells, or a cytotoxic T cell line. Furthermore, our observations provide evidence for the existence of an additional, unknown target of the p38 MAP kinase inhibitor SB203580, the activation of which is essential for mitogenic signaling by IL-2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10066828     DOI: 10.1074/jbc.274.11.7591

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

Authors:  B Foxwell; E Andreakos; F Brennan; M Feldmann; C Smith; M Conron
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  The PTB domain of ShcA couples receptor activation to the cytoskeletal regulator IQGAP1.

Authors:  Matthew J Smith; W Rod Hardy; Guang-Yao Li; Marilyn Goudreault; Steven Hersch; Pavel Metalnikov; Andrei Starostine; Tony Pawson; Mitsuhiko Ikura
Journal:  EMBO J       Date:  2010-01-14       Impact factor: 11.598

3.  The basis of distinctive IL-2- and IL-15-dependent signaling: weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development.

Authors:  Iris Castro; Aixin Yu; Michael J Dee; Thomas R Malek
Journal:  J Immunol       Date:  2011-10-07       Impact factor: 5.422

4.  Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis.

Authors:  T ten Hove; B van den Blink; I Pronk; P Drillenburg; M P Peppelenbosch; S J H van Deventer
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

5.  Inhibition of p38 MAP kinase during cellular activation results in IFN-gamma-dependent augmentation of IL-12 production by human monocytes/macrophages.

Authors:  J B Marriott; I A Clarke; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

6.  TSLP signaling network revealed by SILAC-based phosphoproteomics.

Authors:  Jun Zhong; Min-Sik Kim; Raghothama Chaerkady; Xinyan Wu; Tai-Chung Huang; Derese Getnet; Christopher J Mitchell; Shyam M Palapetta; Jyoti Sharma; Robert N O'Meally; Robert N Cole; Akinori Yoda; Albrecht Moritz; Marc M Loriaux; John Rush; David M Weinstock; Jeffrey W Tyner; Akhilesh Pandey
Journal:  Mol Cell Proteomics       Date:  2012-02-16       Impact factor: 5.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.